At the 2026 UCSF-UCLA PSMA Conference, Lisa Bodei reviews PSMA response biomarkers for lutetium PSMA therapy. She presents data from the TheraP and VISION trials showing that baseline SUV mean, ...
(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...
ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...
ASCO GU 2024 Press Releases Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024 Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% ...
(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Alicia Morgans discussing the incorporation of PSMA PETs in registrational trials. To ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a urology trials in bladder and prostate cancer session and a presentation by Dr. Yi-Jun Shen discussing HERO, a ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a phase II trial of cabozantinib in relapsed refractory germ cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results